Effects of epigallocatechin gallate, L-ascorbic acid, α-tocopherol, and dihydrolipoic acid on the formation of deoxyguanosine adducts derived from lipid peroxidation

Nutrition and Cancer

Volumn 62, Issue 5, 2010, Pages 622-629

  Nath, Raghu G ^a   Wu, Mona Y ^a   Emami, Armaghan ^a   Chung, Fung Lung ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,N2 PROPANODEOXYGUANOSINE; 8 HYDROXYDEOXYGUANOSINE; ACROLEIN DERIVATIVE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; DEOXYGUANOSINE; DEOXYGUANOSINE DERIVATIVE; DIHYDROLIPOATE; DOCOSAHEXAENOIC ACID; EPIGALLOCATECHIN GALLATE; POLYUNSATURATED FATTY ACID; UNCLASSIFIED DRUG; 8-OXO-7-HYDRODEOXYGUANOSINE; ACROLEIN; CATECHIN; CYCLIC 1,N(2)-PROPANODEOXYGUANOSINE; THIOCTIC ACID;

ANTIOXIDANT ACTIVITY; ARTICLE; CHEMICAL MODEL; CONCENTRATION RESPONSE; DNA ADDUCT; DNA DAMAGE; FATTY ACID OXIDATION; LIPID PEROXIDATION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; METABOLISM;

ACROLEIN; ALPHA-TOCOPHEROL; ANTIOXIDANTS; ASCORBIC ACID; CATECHIN; DEOXYGUANOSINE; DNA DAMAGE; DOCOSAHEXAENOIC ACIDS; LIPID PEROXIDATION; THIOCTIC ACID;

EID: 77953995280     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580903532424     Document Type: Article

References (43)

1. Nair U, Bartsch H, and Nair J: Lipid peroxidation-induced DNA damage in cancer-prone inflammatory diseases: a review of published adduct types and levels in humans. Free Radic Biol Med 43, 1109-1120, 2007.
2. Refsgaard HHF, Tsai L, and Stadtman ER: Modifications of proteins by polyunsaturated fatty acid peroxidation products. Proc Natl Acad Sci USA 97, 611-616, 2000.
3. Nair J, De Flora S, Izzotti A, and Bartsch H: Lipid peroxidation-derived etheno-DNA adducts in human atherosclerotic lesions. Mutat Res 621, 95-105, 2007.
4. Negre-Salvayre A, Coatrieux C, Ingueneau C, and Salvayre R: Advanced lipid peroxidation end products in oxidative damage to proteins: potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 153, 6-20, 2008.
5. Marnett LJ: Oxy radicals, lipid peroxidation and DNA damage. Toxicology 181-182, 219-222, 2002.
6. Esterbauer J, Schaur RJ, and Zollner H: Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11, 81-128, 1991.
7. Chung F-L, Young R, and Hecht SS: Formation of cyclic 1,N2- propanodeoxyguanosine adducts in DNA upon reaction with acrolein or crotonaldehyde. Cancer Res 44, 990-995, 1984.
8. Nath RG and Chung F-L: Detection of exocyclic 1,N2- propanodeoxyguanosine adducts as common DNA lesions in rodents and humans. Proc Natl Acad Sci USA 91, 7491-7495, 1994.
9. Pan J and Chung F-L: Formation of cyclic deoxyguanosine adducts from omega-3 and omega-6 polyunsaturated fatty acids under oxidative conditions. Chem Res Toxicol 15, 367-372, 2002.
10. Zhang S,Villalta PW,WangM, and Hecht SS: Detection and quantitation of acrolein-derived 1,N2-propanodeoxyguanosine adducts in human lung by liquid chromatography-electrospray ionization-tandem mass spectrometry. Chem Res Toxicol 20, 565-571, 2007.
11. Marnett LJ, Hurd HK, Hollstein MC, Levin DE, Esterbauer H, et al.: Naturally occurring carbonyl compounds are mutagens in salmonella tester strain TA104. Mutat Res 148, 25-34, 1985.
12. Foiles PG, Akerkar SA, and Chung F-L: Application of an immunoassay for cyclic acrolein deoxyguanosine adducts to assess their formation in DNA of Salmonella typhimurium under conditions of mutation induction by acrolein. Carcinogenesis 10, 87-90, 1989.
13. Foiles PG, Akerkar SA, Miglietta LM, and Chung F-L: Formation of cyclic deoxyguanosine adducts in Chinese hamster ovary cells by acrolein and crotonaldehyde. Carcinogenesis 11, 2059-2061, 1990.
14. Yang I-Y, Chan G, Miller H, Huang Y, Torres MC, et al.: Mutagenesis by acrolein-derived propanodeoxyguanosine adducts in human cells. Biochemistry 41, 13826-13832, 2002.
15. Yang I-Y, Hossain M, Miller H, Khullar S, Johnson F, et al.: Responses to the major acrolein-derived deoxyguanosine adduct in Escherichia coli. J Biol Chem 276, 9071-9076, 2001.
16. VanderVeen LA, Hashim MF, Nechev LV, Harris TM, Harris CM, et al.: Evaluation of the mutagenic potential of the principal DNA adduct of acrolein. J Biol Chem 12, 9066-9070, 2001.
17. Cohen SM, Garland EM, St. John M, Okamura T, and Smith RA: Acrolein initiates rat urinary bladder carcinogenesis. Cancer Res 52, 3577-3581, 1992.
18. Khan MA, Travis LB, Lynch CF, SoiniY,Hruszkewycz AM, et al.: p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev 7, 397-403, 1998.
19. Roemer E, Stabbert R, Rustemeier K, Veltel DJ, Meisgen TJ, et al.: Chemical composition, cytotoxicity andmutagenicity of smoke from US commercial and reference cigarettes smoked under two sets of machine smoking conditions. Toxicology 195, 31-52, 2004.
20. Nath RG, Ocando JE, Guttenplan JB, and Chung F-L: 1,N2- Propanodeoxyguanosine adducts: potential new biomarkers of smokinginduced DNA damage in human oral tissue. Cancer Res 58, 581-584, 1998.
21. Feng Z, Hu W, Hu Y, and Tang M-S: Acrolein is a major cigarette-related lung cancer agent: preferential binding at p53 mutational hotspots and inhibition of DNA repair. Proc Natl Acad Sci USA 103, 15404-15409, 2006.
22. Frei B and Higdon JV: Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 133, 3275S-3284S, 2003.
23. MoiniH, Packer L, and Saris N-EL: Antioxidant and prooxidant activities of ?-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol 182, 84-90, 2002.
24. Fodor G, Arnold R, Mohacsi T, Karle I, and Flippen-Anderson J: A new role for L-ascorbic acid: Michael donor to unsaturated carbonyl compounds. Tetrahedron 39, 2137-2145, 1983.
25. Park JW and Floyd RA: Lipid peroxidation products mediate the formation of 8-hydroxydeoxyguanosine in DNA. Free Radic Biol Med 12, 245-250, 1992.
26. Carr A and Frei B: Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J 13, 1007-1024, 1999.
27. Yamamoto K and Niki E: Interaction of 1-tocopherol with iron: antioxidant and prooxidant effects of 1-tocopherol in the oxidation of lipids in aqueous dispersions in the presence of iron. Biochim Biophys Acta 958, 19-23, 1988.
28. Furukawa A, Oikawa S, Murata M, Hiraku Y, Kawanishi S: Epigallocatechin gallate causes oxidative damage to isolated and cellular DNA. Biochem Pharmacol 66, 1769-1778, 2003. (Pubitemid 37249321)
29. Azam S, Hadi N, Khan NU, and Hadi SM, Prooxidant property of green tea polyphenols epicatechin and epigallocatechin-3-gallate: implications for anticancer properties. Toxicol In Vitro 18, 555-561, 2004.
30. Lyberg A-M and Adlercreutz P: Monitoring monohydroperoxides in docosahexaenoic acid using high-performance liquid chromatography. Lipids 41, 67-76, 2006.
31. Chen H-JC and Chung F-L: Epoxidation of trans-4-hydroxy-2-nonenal by fatty acid hydroperoxides and hydrogen peroxide. Chem Res Toxicol 9, 306-312, 1996.
32. Beretta G, Furlanetto S, Regazzoni L, Zarrella M, and Facino RM: Quenching of alpha,beta-unsaturated aldehydes by green tea polyphenols: HPLCESI- MS/MS studies. Pharm Biomed Anal 48, 606-611, 2008.
33. Niedernhofer LJ, Riley M, Schnetz-Boutaud N, Sanduwaran G, Chaudhary AK, et al.: Temperature-dependent formation of a conjugate between tris(hydroxymethyl)aminomethane buffer and the malondialdehyde-DNA adduct pyrimidopurinone. Chem Res Toxicol 10, 556-561, 1997.
34. Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, and Bay WH: Effect of phosphate binders on supplemental iron absorption in healthy subjects. J Clin Pharmacol 42, 1171-1176, 2002.
35. Najean Y, Castro-Malaspina H, Colonna P, and Dresch C: The influence of circadian variations in plasma iron on the measure of plasma iron turnover. Eur J Nucl Med 2, 189-191, 1977.
36. Schafer FQ, Qian SY, and Buettner GR: Iron and free radical oxidations in cell membranes. Cell Mol Biol 46, 657-662, 2000.
37. Lee M-J, Maliakal P, Chen L, Meng X, Bondoc FY, et al.: Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin- 3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 11, 1025-1032, 2002.
38. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, et al.: Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 93, 3704-3709, 1996.
39. Hatam LJ and Kayden HJ: A high-performance liquid chromatographic method for the determination of tocopherol in plasma and cellular elements of the blood. J Lipid Res 20, 639-645, 1979.
40. Teichert J, Tuemmers T, Achenbach H, Preiss C, Hermann R, et al.: Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. J Clin Pharmacol 45, 313-328, 2005.
41. Graumlich JF, Ludden TM, Conry-Cantilena C, Cantilena LR Jr.,Wang Y, et al.: Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm Res 14, 1133-1139, 1997.
42. Blatt DH, Leonard SW, and Traber MG:Vitamin E kinetics and the function of tocopherol regulatory proteins. Nutrition 17, 799-805, 2001.
43. Packer L, Witt EH, and Tritschler HJ: Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 19, 227-250, 1995.